LAVIPHARM S.A. NA EO 1 Total Liabilities
LAVIPHARM S.A. NA EO 1 total liabilities. Based on the latest financial reports, LAVIPHARM S.A. NA EO 1 (BXA0) has total liabilities worth €72.52 Million EUR (≈ $84.78 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LAVIPHARM S.A. NA EO 1 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of LAVIPHARM S.A. NA EO 1 (2021–2024)
Total liabilities of LAVIPHARM S.A. NA EO 1 from 2021 to 2024. This chart illustrates how LAVIPHARM S.A. NA EO 1's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of LAVIPHARM S.A. NA EO 1 to evaluate the company's liquid asset resilience ratio.
LAVIPHARM S.A. NA EO 1 Competitors by Total Liabilities
The table below lists competitors of LAVIPHARM S.A. NA EO 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heng Sheng Holding Group Limited
KQ:900270
|
Korea | ₩52.60 Billion |
|
Chalice Mining Ltd
AU:CHN
|
Australia | AU$6.43 Million |
|
Hefei Jingsong Intelligent Technology Co. Ltd. A
SHG:688251
|
China | CN¥906.32 Million |
|
Novabase SGPS
LS:NBA
|
Portugal | €67.20 Million |
|
Beijing Hanjian Heshan Pipeline Co Ltd
SHG:603616
|
China | CN¥1.13 Billion |
|
Camil Alimentos S.A
SA:CAML3
|
Brazil | R$7.91 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down LAVIPHARM S.A. NA EO 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LAVIPHARM S.A. NA EO 1 (BXA0) total assets.
Liquidity & Leverage Metrics
LAVIPHARM S.A. NA EO 1 Total Liabilities Ratios Explained
LAVIPHARM S.A. NA EO 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LAVIPHARM S.A. NA EO 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below shows the annual total liabilities of LAVIPHARM S.A. NA EO 1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €72.52 Million ≈ $84.78 Million |
+0.70% |
| 2023-12-31 | €72.02 Million ≈ $84.19 Million |
-2.49% |
| 2022-12-31 | €73.86 Million ≈ $86.34 Million |
+17.83% |
| 2021-12-31 | €62.68 Million ≈ $73.28 Million |
-- |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more